Health officials believe the newly formulated shots will offer stronger protection against severe COVID-19 as we head into the fall and winter
from the date symptoms first appeared or the date of a positive test result.
until they get their COVID-19 jab. This is mainly due to an unknown risk of rare heart conditions arising from taking the Jynneos monkeypox vaccine.The durability of protection conferred by these updated vaccines remains unknown. “That’s the million-dollar question—how long will immunity last,” says Kanta Subbarao, director of the World Health Organization's technical vaccine committee. “We still don’t understand what we need to do to elicit durability.
The United Kingdom, on the other hand, has authorized the use of bivalent vaccines containing the ancestral strain and the original BA.1 strain. It’s possible the country may switch to shots that also include BA.4 and BA.5.6. What we know and don’t we know about these boosters?They relied on experiments Moderna and Pfizer-BioNTech conducted in mice, which showed higher antibody levels against BA.4 and BA.5 using the new booster versus the original formulation.